A retrospective study found that CD30 expression was detectable in 57% of patients with extranodal peripheral T-cell lymphomas (PTCLs) at a 5% threshold, suggesting that CD30-targeted therapy may be an effective treatment for PTCLs [12]. The gene discussed is TNFRSF8; the disease is peripheral T-cell lymphoma, not otherwise specified.